TAMPA, FL and LONDON – March 17, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) …
[Read more...] about Akari Therapeutics Announces ADS Ratio Change
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline …
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
Recognized expert in cancer biology, RNA biology and translational therapeutics with 20 years of experience in preclinical oncology drug discovery and …
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and …
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
In-person presentation on Wednesday, February 25th at 11:00 AM PTTAMPA, FL and LONDON – February 18, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology …
